Show Search Form
human indexable | ||||||||
---|---|---|---|---|---|---|---|---|
published | ||||||||
registered interest | ||||||||
answer date | ||||||||
date | ||||||||
date tabled | ||||||||
ddp created | ||||||||
answering body |
|
|||||||
question status | Tabled | |||||||
answering dept id | 17 | |||||||
answering dept short name | Health | |||||||
answering dept sort name | Health | |||||||
ddp modified |
|
|||||||
hansard heading | Drugs: Intellectual Property | |||||||
house id | 2 | |||||||
identifier | HL2897 | |||||||
legislature |
|
|||||||
parliament number | 57 | |||||||
question first answered |
|
|||||||
question text | To ask Her Majesty's Government what incentives, if any, they plan to introduce to ensure that, following Brexit, firms continue to develop intellectual property in the UK, including for paediatric products and orphan medicines; and whether, in so doing, they will take into account any recommendations arising out of the European Commission’s current analysis of intellectual property incentives for the pharmaceutical industry. | |||||||
session |
|
|||||||
session number | 1 | |||||||
tabling member printed |
|
|||||||
title | House of Lords Tabled Parliamentary Question 2017/19 HL2897 | |||||||
type |
|
|||||||
uin | HL2897 | |||||||
version | 2 | |||||||
written parliamentary question type | Ordinary | |||||||
answer | answer | |||||||
creator |
|
|||||||
publisher |
|
|||||||
tabling member |
|